U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389590) titled 'Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis' on Jan. 29.
Brief Summary: The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
Intervention:
DRUG: Ublituximab
Ublituzimab will be administered via IV infusion as specified throughout the study period.
DRU...